ALC logo

Alcon Inc. Stock Price

SWX:ALC Community·CHF 30.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author

ALC Share Price Performance

CHF 60.62
-21.52 (-26.20%)
38.4% undervalued intrinsic discount
CHF 98.45
Fair Value
CHF 60.62
-21.52 (-26.20%)
38.4% undervalued intrinsic discount
CHF 98.45
Fair Value
Price CHF 60.62
AnalystHighTarget CHF 98.45
AnalystConsensusTarget CHF 81.30
AnalystLowTarget CHF 62.32

ALC Community Narratives

AnalystHighTarget·
Fair Value CHF 98.45 37.7% undervalued intrinsic discount

Unity VCS And LumiThera Will Drive Global Eye Care Transformation

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value CHF 81.3 24.6% undervalued intrinsic discount

Global Aging And Emerging Markets Will Expand Eye Care

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AnalystLowTarget·
Fair Value CHF 62.32 1.6% undervalued intrinsic discount

Government Price Cuts Will Compress Margins Though Telemedicine Supports

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent ALC News & Updates

Is Now The Time To Put Alcon (VTX:ALC) On Your Watchlist?

Aug 14
Is Now The Time To Put Alcon (VTX:ALC) On Your Watchlist?

Earnings Tell The Story For Alcon Inc. (VTX:ALC)

Jul 02
Earnings Tell The Story For Alcon Inc. (VTX:ALC)

Alcon Inc. Key Details

US$10.0b

Revenue

US$4.5b

Cost of Revenue

US$5.6b

Gross Profit

US$4.5b

Other Expenses

US$1.1b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 12, 2025
Earnings per share (EPS)
2.17
Gross Margin
55.56%
Net Profit Margin
10.70%
Debt/Equity Ratio
21.4%

Alcon Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and good value.

0 Risks
3 Rewards

About ALC

Founded
1945
Employees
25000
CEO
David Endicott
WebsiteView website
www.alcon.com

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Swiss Market Performance

  • 7 Days: 1.6%
  • 3 Months: 4.2%
  • 1 Year: 3.6%
  • Year to Date: 7.0%
The market has climbed 1.6% in the last 7 days, lead by the Healthcare sector with a gain of 2.9%. As for the past 12 months, the market is up 3.6%. Earnings are forecast to grow by 11% annually. Market details ›